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at lower cost compared with gabapentin as monotherapy. Resulting in greater
satisfaction and better adherence to treatment.
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ECONOMIC EVALUATION OF PANITUMUMAB VS CETUXIMAB IN PATIENTS
WITH COLORECTAL CARCINOMA (CRCM) WITH NON-MUTATED (WILD-TYPE)
KRAS AFTER FAILURE OF CHEMOTHERAPY REGIMENS IN MEXICO
Arocho R1, Rivera Hurtado R2
1Amgen, Inc., Barcelona, Spain, 2Amgen México, México D.F., México
OBJECTIVES: Panitumumab, a fully human monoclonal antibody directed against
epidermal growth factor receptor (EGFR), is indicated as a monotherapy for the
treatment of patients with EGFR-expressing CRCm and non-mutated KRAS status.
The aim of this study was to conduct an economic evaluation of panitumumab vs
cetuximab in Mexican patients with CRCm. METHODS: A cost minimization anal-
ysis (CMA) was performed from a Public Healthcare System perspective consider-
ing a 20-week timeframe. The analysis compared the treatment costs of CRCm
patients with panitumumab and cetuximab. Only direct medical costs were con-
sidered. Drug cost for cetuximab was calculated according to Mexican Public
Healthcare Sector acquisition price list for 2010. Panitumumab price for the Mexi-
can Public Healthcare Sector was provided by Amgen Mexico ($94.36 MXP/mg).
Recommended doses and frequency were based on each product label and the
number of cycles was based on data from clinical trials. Anthropometric values
were obtained from published data in Mexican Public Healthcare Sector oncology
(CRCm) patients. The cost of administration was calculated from an official Mexi-
can Public Healthcare Sector price list for 2010. A probabilistic sensitivity analysis
was performed considering two scenarios: per vial of drug (assuming wastage of
unused medication) and per mg of drug (assuming no wastage). RESULTS: Panitu-
mumab resulted in an overall monthly cost savings of 20% (per vial scenario) and
12.4% (per mg sceanrio) compared with cetuximab. When the analysis was re-
stricted to the acquisition drug costs, monthly savings of panitumumab compared
with cetuximab were estimated to be 19.1% and 11.2% in per vial and per mg
scenarios, respectively. Regarding the sensitivity analysis, 100% of iterations re-
sulted cost-saving in both scenarios (per vials and per mg).CONCLUSIONS:Accord-
ing to these results, panitumumab represents a cost-saving strategy vs cetuximab
for the treatment of patients with CRCm in the Mexican setting.
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ANALISIS DE MINIMIZACION DE COSTOS ENTRE EL USO DE IOPROMIDE
MEDIANTE UN SISTEMA DE APLICACION EN CASCADA (SIAC) FRENTE AL USO
DE OTROS MEDIOS DE CONTRASTE CONVENCIONALES EN RADIOLOGIA
INVASIVA EN COLOMBIA
Romero M1, Karpf E1, Oyuela M2
1Fundación Salutia, Bogotá, Colombia, 2Bayer Colombia, Bogotá, Colombia
OBJECTIVOS: Realizar una evaluación económica del uso de Iopromide mediante
un sistema de aplicación en cascada (SIAC), frente a los demás medios de contraste
para radiología invasiva disponibles en Colombia e incluidos dentro del plan de
beneficios colombiano (POS). METODOLOGÍAS: Se realizó un análisis de minimi-
zación de costos comparando SIAC frente al uso de otros medios de contraste
convencionales en radiología invasiva desde la perspectiva del hospital. La efec-
tividad y seguridad del uso de Iopromide es similar a la de los ya incluidos en el POS
según reportes de estudios clínicos. Los costos y frecuencias de uso fueron obteni-
dos de tres hospitales en Colombia durante el primer trimestre del 2011. Se toma-
ron los costos promedios obtenidos de las diferentes observaciones. No se incluy-
eron costos por eventos adversos, por cuanto son similares en las diferentes
opciones. RESULTADOS: El costo de utilizar SIAC en un paciente promedio de 70 Kg
fue de USD 35.57 frente a USD 39.44 cuando se utilizó otros medios de contraste
convencional. Lo que representa un ahorro de USD 3.90 por paciente. La diferencia
fundamental se debió a menor desperdicio de medio de contraste y menor tiempo
requerido. El análisis de sensibilidad no muestra cambios en los resultados. El
análisis de impacto presupuestario muestra el importante ahorro que significaría
para el país la conversión tecnológica pasando de utilizar los medios actuales a la
nueva tecnología que utiliza el sistema de aplicación SIAC para un peso promedio
de adultos en Colombia de 70 kg. CONCLUSIONES: El uso de Iopromide mediante la
aplicación de SIAC sería mejor que utilizar otros medios de contraste por cuanto es
menos costoso y utilizado de manera adecuada tendrían igual efectividad a los
otros medios de contraste comparados y de esta manera incentiva la productividad
al interior de las unidades de radiología.
Cardiovascular Disorders – Cost Studies
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COSTS, LENGTH OF STAY AND ALL-CAUSE MORTALITY IN RUPTURED VERSUS
UNRUPTURED CEREBRAL ANEURYSM AMONG INPATIENTS IN THE UNITED
STATES
Wallace KL, Hashemi L, Minshall ME
Covidien, Mansfield, MA, USA
OBJECTIVES: Cerebral aneurysms are pathological dilatations of the cerebrovascu-
lature that are prone to rupture. Risk of aneurysm rupture is determined by size,
location and patient co-morbidies, and five-year cumulative rupture rates have
been reported to be as high as 50% in giant aneurysms [1]. The current study was
undertaken to assess the differences in overall hospital discharge costs, length of
stay (LOS) and all-cause mortality rates between inpatients with ruptured versus.
unruptured cerebral aneurysms.METHODS:All inpatient discharges were selected
from the Premier Perspective™ Database that had a primary diagnosis code for a
ruptured or unruptured aneurysm, AND a primary procedure code for treatment of
the aneurysm between 1/1/2008 and 6/30/2010 (index hospitalization). Costs, LOS
and mortality were compared between ruptured and unruptured aneurysm
groups. To minimize differences in baseline characteristics between groups, pro-
pensity adjustment was performed for age, gender and severity of illness (based on
the Patient Refined Diagnosis Related Groups). RESULTS: A total of 2977 ruptured
and 3836 unruptured aneurysm discharges met the inclusion criteria for the study.
After 1:1 propensity matching, 1163 patients in each group were included in the
analysis for outcome comparisons. Mean total cost per discharge was significantly
higher in the ruptured group ($51,118, s.d. $33,790) than the unruptured group
($33,585, s.d. $32,255). Mean LOS was also significantly higher in the ruptured group
(13.6 days, s.d. 12.7) versus. the unruptured group (6.5 days, s.d. 11.2). The all-cause
mortality rate was significantly higher in ruptured (7.7%) versus. unruptured (1.8%)
cerebral aneurysms. CONCLUSIONS: Preventing rupture in patients with cerebral
aneurysms would likely decrease burden to the health care system, and also im-
prove survival rates for patients. 1International Study of Unruptured Intracranial
Aneurysms Investigators. Unruptured Intracranial Aneurysms: Natural History,
Clinical Outcome, and Risks of Surgical and Endovascular Treatment. ([1] Lancet;
2003; 362:103-10)
PCV2
ESTIMATED COST OF ACUTE CORONARY SYNDROME FOR 2011: CASE OF
MEXICO
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OBJECTIVES: To estimate the costs of acute coronary syndrome in Mexico and its
impact on the Mexican healthcare system, considering direct and indirect cost
under the public and private perspectives to support further HTA incorporation.
METHODS: In this study we adopted the societal perspective, including the public
and private perspectives. Direct costs were retrieved from national databases and
only hospitalization period was considered. For indirect costs the Human Capital
Approach method was used with two major costs included in the analysis: loss of
productivity among patients that died of a MI or unstable angina event and the loss
of productivity of the period between the main event (MI or angina) and the return
to work (recovery time). For the study we assumed the age from 25 to 64 years old
as active labor age (65 is the age of retirement in Mexico), a recovery time of 3.4
months and the average income of the population to estimate the loss of produc-
tivity for each working month lost. RESULTS: The estimated direct costs associated
to Acute Coronary Syndrome for 2011 under the public perspective is
US$153,629,253 and for private it is US$179,725,285. The estimated indirect cost for
2011 is US$918,239,181. So, the total estimated costs for ACS in Mexico for 2011 is
US$1,251,593,719. CONCLUSIONS: Due the high impact of ACS costs for the Mexi-
can healthcare system (U$1,251,593,719), projected for the year of 2011, it is very
relevant to evaluate measures that can reduce such events beyond those already in
use.
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ESTIMATED COST OF ACUTE CORONARY SYNDROME FOR 2011: CASE OF
BRAZIL
Piha T1, Ramirez MA2, Sanchez A2, Mariz VO1, Neves JE3, Teich V4, Araujo DV4
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OBJECTIVES: To estimate the costs of acute coronary syndrome in Brazil and its
impact on the Brazilian healthcare system, considering direct and indirect cost
under the public and private perspectives to support further HTA incorporation.
METHODS: In this study we adopted the societal perspective, including the public
(SUS) and supplementary (SHS) healthcare system perspectives. Direct costs were
retrieved from national databases [1] and only hospitalization period was consid-
ered. For indirect costs the Human Capital Approach method was used with two
major costs included in the analysis: loss of productivity among patients that died
of a MI or unstable angina event and the loss of productivity of the period between
the main event (MI or angina) and the return to work (recovery time). For the study
we assumed the age from 25 to 64 years old as active labor age (65 is the age of
retirement in Brazil), a recovery time of 3.4 months and the average income of the
population to estimate the loss of productivity for each working month lost.
RESULTS: The estimated direct costs associated to Acute Coronary Syndrome for
2011 under the SUS perspective is US$ 314,080,370 and for SHS it is US$ 309,781,809.
The estimated indirect cost for 2011 is US$ 1,703,908,984. So, the total estimated
costs for ACS in Brazil for 2011 is US$ 2,327,771,163. CONCLUSIONS: Due the high
impact of ACS costs for the Brazilian healthcare system (U$ 2,327,771,163.11), pro-
jected for the year of 2011, it is very relevant to evaluate measures that can reduce
such events beyond those already in use.
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ANALISIS COSTO EFECTIVIDAD EN EL LARGO PLAZO DE LOS STENTS
LIBERADORES DE FARMACO VS STENTS CONVENCIONALES EN PACIENTES CON
CARDIOPATIA ISQUEMICA EN EL IMSS
Gonzalez-Diaz BE1, Salinas Escudero G2, Granados-Garcia V1, Contreras Hernández I1,
Calderón Abbo M1
1Instituto Mexicano del Seguro Social, México D.F., México, 2Hospital Infantil de México Federico
Gómez, Secretaría de Salud, México D.F., México
OBJECTIVOS: Estimar la razón costo-efectividad (RCE) del uso de los stents libera-
dores de fármaco (DES, drug eluting stent) comparado contra los stents desnudos
(BMS, bare metal stent) en una cohorte de pacientes con enfermedad coronaria en
el Instituto Mexicano del Seguro Social (IMSS). METODOLOGÍAS: Análisis de costo-
efectividad en una cohorte de pacientes isquémicos con indicación de ICP (Inter-
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vención Coronaria Percutánea). La medida de efectividad fue la tasa de éxitos clíni-
cos sin eventos adversos cardiovasculares mayores a 3 años. El costo y la
efectividad los tratamientos se obtuvo del seguimiento clínico de la cohorte de
n230 pacientes en el Hospital de Cardiología del IMSS seguidos por 3 años. Se
utilizó la técnica de micro-costeo, los costos provienen de bases de costos institu-
cionales (2010). Los resultados están expresados en dólares americanos (USD) del
2010 (tipo de cambio MX$12.63: $1 USD). Se empleó una tasa de descuento del 5%.
Además del modelo determinístico, se realizó un análisis de sensibilidad proba-
bilístico y se estimó la curva de aceptabilidad. RESULTADOS: El 59.3% de los paci-
entes de la cohorte utilizó BMS y el 40.87% DES. El grupo con DES mostró los may-
ores costos promedio por paciente USD$16,635 comparado con BMS USD$13,432.
Las efectividades DES encontradas fueron de 88% y las de BMS 74%. La RCE fue de
USD$15,263 en el caso de DES y de USD$22,480 con BMS. El DES se ubicó como la
alternativa costo-efectiva y dominante frente al empleo del BMS. La curva de acept-
abilidad muestra que el tratamiento de DES se ubicó como la alternativa costo-
efectiva independientemente de la Disponibilidad a Pagar por parte de la
institución. CONCLUSIONES: Los resultados del análisis realizado sugieren que
DES es una alternativa de tratamiento intervencionista de revascularización con
mejores resultados en salud, y que también representa una alternativa costo ahor-
radora respecto a BMS.
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COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF RIVAROXABAN IN
THE PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS PERFORMING
HIP AND KNEE ARTHROPLASTY IN COMPARISON WITH NO TREATMENT
UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
Schiola A1, Silva AP2, Santoni NB2, Paladini L3, Teich V3, Pepe C3, Rocha MM3
1Bayer de México, S.A. de C.V., México D.F., México, 2Bayer Brasil, São Paulo, SP, Brazil,
3MedInsight Evidências, São Paulo, SP, Brazil
OBJECTIVES: To develop a cost-effectiveness and a budget impact analysis of Ri-
varoxaban in the prevention of thromboembolic events in patients performing hip
and knee arthroplasty in comparison with no treatment under the Brazilian private
health care system perspective.METHODS:A decision tree analysis was developed
for the first 90 days, considering the occurrence of Deep Venous Thrombosis, Pul-
monary Embolism and thromboembolic events, followed by a Markov model, for
Post Thrombotic Syndrome and Thrombotic Pulmonary Hypertension. The time
horizon of the analysis was 5 year. The cycle duration was 1 year and the corre-
sponding epidemiological and efficacy data were obtained from a critical appraisal
of the scientific literature. Unit costs for drugs, procedures, materials and daily
hospital were obtained from Kairos Magazine (Maximum price consumers
18%ICMS), Hierarchical Brazilian Classification of Medical Procedures (CBHPM 5th
edition), Simpro Magazine Maximum price consumers 18% ICMS) and search UNI-
DAS 2008, respectively. A budget impact analysis was developed considering an
increase of 10% per year in market share of Rivaroxaban. RESULTS: Total costs
associated with Rivaroxaban and no treatment, considering the indication for knee
arthroplasty, were BRL363 (US$214) and BRL1,040 (US$612), respectively. And con-
sidering the indication for hip arthroplasty, were BRL332 (US$195) and BRL462
(US$272), respectively. Rivaroxaban reduces the number of all thromboembolic
events in 0.0793 and 0.0246, for knee and hip arthroplasty, respectively. Rivaroxa-
ban treatment is more effective and cheaper than no treatment in both indications
(dominant). The high cost associated with no treatment patient is due to the high
number of events in this group. The budget impact analysis estimated an economy
of BRL206,165 (US$121,274) and BRL104,351 (US$61,383) for knee and hip indication,
respectively, in 5 years. CONCLUSIONS: By this pharmacoeconomic analysis, the
treatment with Rivaroxaban, shown to reduce treatment costs and events com-
pared with no treatment.
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COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF RIVAROXABAN IN
THE PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS PERFORMING
HIP AND KNEE ARTHROPLASTY IN COMPARISON WITH ENOXAPARIN UNDER
THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
Schiola A1, Silva AP2, Santoni NB2, Paladini L3, Teich V3, Pepe C3, Rocha MM3
1Bayer de México, S.A. de C.V., México D.F., México, 2Bayer Brasil, São Paulo, SP, Brazil,
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OBJECTIVES: To develop a cost-effectiveness and a budget impact analysis of Ri-
varoxaban in the prevention of thromboembolic events in patients performing hip
and knee arthroplasty in comparison with Enoxaparin under the Brazilian private
health care system perspective.METHODS:A decision tree analysis was developed
for the first 90 days, considering the occurrence of Deep Venous Thrombosis, Pul-
monary Embolism and thromboembolic events, followed by a Markov model, for
Post Thrombotic Syndrome and Thrombotic Pulmonary Hypertension. The time
horizon of the analysis was 5 year. The cycle duration was 1 year and correspond-
ing epidemiological and efficacy data were obtained from a critical appraisal of the
scientific literature. The outcomes were expressed as the incremental number of
all thromboembolic events. The analysis considered only direct medical costs. Unit
costs for drugs, procedures, materials and daily hospital were obtained from Kairos
Magazine (Maximum price consumers 18% ICMS), Hierarchical Brazilian Classifi-
cation of Medical Procedures (CBHPM 5thedition), Simpro Magazine (Maximum
price consumers 18%ICMS) and UNIDAS 2008, respectively. A budget impact anal-
ysis was developed considering an increase of 10% per year in market share of
Rivaroxaban. RESULTS: Total costs associated with Rivaroxaban and Enoxaparin,
considering the indication for knee arthroplasty, were BRL363 (US$214) and BRL632
(US$372), respectively. Rivaroxaban reduces the number of all thromboembolic
events in 0.0167. Rivaroxaban treatment is more effective and cheaper than Enoxa-
parin treatment (dominant). Total costs associated with Rivaroxaban and Enoxa-
parin, considering the indication for hip arthroplasty, were BRL332 (US$195) and
BRL468 (US$275), respectively. The number of all thromboembolic events was the
same. Rivaroxaban treatment is cheaper with same efficacy. The budget impact
analysis estimated an economy of BRL98,810 (US$58,124) and BRL184,630
(US$108,606) for knee and hip indication, respectively, in 5 years. CONCLUSIONS:
By this pharmacoeconomic analysis, the treatment with Rivaroxaban, shown to
reduce treatment costs and events compared with Enoxaparin.
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COST-EFFECTIVENESS OF PRASUGREL VERSUS CLOPIDOGREL IN PATIENTS
WITH ACUTE CORONARY SYNDROMES UNDERGOING PERCUTANEOUS
CORONARY INTERVENTION IN THE PUBLIC HEALTH CARE SYSTEM IN MEXICO
Mondragon R1, Arrieta-Maturino E2, Vargas-Valencia JJ3, Martínez-Fonseca J3,
Guzman-Sotelo M3, Galindo-Suarez RM2, Ramírez-Gámez J2
1Hospital Central-Sur de Alta Especialidad PEMEX, México D.F., México, 2Eli Lilly and Company,
México D.F., México, 3Econopharma Consulting S.A. de C.V., México D.F., México, 4Pfizer, Inc.,
México City, México
OBJECTIVES: To evaluate the cost-effectiveness of prasugrel versus clopidogrel in
patients with acute coronary syndromes (ACS) undergoing percutaneous coronary
intervention (PCI) from the public healthcare payer perspective in Mexico.
METHODS: The alternatives were prasugrel (loading dose 60 mg, maintenance
dose 10 mg daily) versus clopidogrel (loading dose 300 mg, maintenance dose 75 mg
daily). A Markov model was developed. Only direct medical care costs were con-
sidered for one year. The efficacy measure was a composite of the death from
cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke and stent
thrombosis reported in the trial directly comparing prasugrel and clopidogrel (TRI-
TON TIMI-38). Three types of populations were evaluated separately; overall, pa-
tients with diabetes mellitus, and the subset of diabetics treated with insulin. Care
costs were derived from medical records, and the costs of drugs were assumed to
be the same. Costs and the model were validated by experts. RESULTS: According
to the model prasugrel had fewer events in the three types of populations evalu-
ated over a 12 month time horizon. The number of events; death from cardiovas-
cular causes, nonfatal myocardial infarction-stroke and stent thrombosis avoided
by 10,000 patients were distributed as follows: overall population, 31, 650 and 147,
diabetics, 92, 1363 and 203, diabetics on insulin, 174, 2531 and 499. The average cost
per patient (2010 Mexican pesos) treated with prasugrel was lower compared with
clopidogrel, for the overall population (MXN$ 69,972 vs. MXN$ 82,991), diabetics
(MXN$79,971 vs. MXN$ 105,756) and diabetics treated with insulin (MXN$ 85,750 vs.
MXN$ 137,144). CONCLUSIONS: Results from the present analysis suggest that the
use of prasugrel (instead of clopidogrel) in patients with ACS undergoing PCI rep-
resents a more effective strategy at a lower cost (dominant strategy), a cost-saving
alternative for institutions of public healthcare in Mexico.
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COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF RIVAROXABAN IN
THE PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS PERFORMING
HIP AND KNEE ARTHROPLASTY IN COMPARISON WITH DABIGATRAN UNDER
THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
Schiola A1, Silva AP2, Santoni NB2, Paladini L3, Teich V3, Pepe C3, Rocha MM3
1Bayer de México, S.A. de C.V., México D.F., México, 2Bayer Brasil, São Paulo, SP, Brazil,
3MedInsight Evidências, São Paulo, SP, Brazil
OBJECTIVES: To develop a cost-effectiveness and a budget impact analysis of Ri-
varoxaban in the prevention of thromboembolic events in patients performing hip
and knee arthroplasty in comparison with Dabigatran under the Brazilian private
health care system perspective.METHODS:A decision tree analysis was developed
for the first 90 days, considering the occurrence of Deep Venous Thrombosis, Pul-
monary Embolism and thromboembolic events, followed by a Markov model, for
Post Thrombotic Syndrome and Thrombotic Pulmonary Hypertension. The time
horizon of the analysis was 5 year. The cycle duration was 1 year and correspond-
ing epidemiological and efficacy data were obtained from a critical appraisal of the
scientific literature. The outcomes were expressed as the incremental number of
all thromboembolic events. The analysis considered only direct medical costs. Unit
costs for drugs, procedures, materials and daily hospital were obtained from Kairos
Magazine (Maximum price consumers 18%ICMS), Hierarchical Brazilian Classifica-
tion of Medical Procedures (CBHPM 5thedition), Simpro Magazine (Maximum price
consumers 18%ICMS) and UNIDAS 2008, respectively. A budget impact analysis
was developed considering an increase of 10% per year in market share of
Rivaroxaban. RESULTS: Total costs associated with Rivaroxaban and Dabigatran,
considering the indication for knee arthroplasty, were BRL363 (US$214) and BRL371
(US$218), respectively. The number of all thromboembolic events was the same.
Rivaroxaban treatment is cheaper with same efficacy. Total costs associated with
Rivaroxaban and Dabigatran, considering the indication for hip arthroplasty, were
BRL332 (US$195) and BRL485 (US$285), respectively. Rivaroxaban reduces the num-
ber of all thromboembolic events in 0.0140. Rivaroxaban treatment is more effec-
tive and cheaper than Dabigatran treatment (dominant). The budget impact anal-
ysis estimated an economy of BRL3,894 (US$2,291) and BRL150,642 (US$88,613) for
knee and hip indication, respectively, in 5 years.CONCLUSIONS: By this pharmaco-
economic analysis, the treatment with Rivaroxaban, shown to reduce treatment
costs and events compared with Dabigatran.
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COSTO–EFECTIVIDAD DE LOS ÁCIDOS GRASOS OMEGA 3 COMO
COADYUVANTE DE LA SIMVASTATINA EN EL TRATAMIENTO DE LA
HIPERTRIGLICERIDEMIA
Rendon D, Ordoñez J, Orozco JJ
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